search
Back to results

Effect of Acupressure in Migraine: Single-blinded, Randomized, Controlled Clinical Trial

Primary Purpose

Migraine; Status

Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Acupressure elastic band (Sea-Band)
General elastic band (no bud)
Sponsored by
National Taiwan University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Migraine; Status focused on measuring migraine ,acupressure,CGRP,neurokinin A

Eligibility Criteria

20 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

A. Inclusion criteria

  1. Age ranged from 20 to 50-year-old (inclusion)
  2. Female or male.
  3. Neurological examination was within normal limit.
  4. Neither epileptiform discharge from EEG nor abnormality of neuroimage

B. Exclusion criteria

  1. Headache was results from adverse effects for NSAIDs and Propranolol.
  2. Active skin lesion or oozing wound over PC6 acupoints.
  3. Pregnancy or lactation.
  4. Recent traumatic brain injury or brain tumor.
  5. Secondary headache
  6. Brain surgical history.
  7. Refuse sign informed consent.
  8. Extremely abnormal metabolic disturbance (such as iron deficiency anemia, hypo/hypernatremia, hypo/hyperkalemia, hypo/hypercalcemia, hypo/ hypermagnesemia) and liver/renal dysfunction ALT > 3x normal upper limits; creatinine >1.4)

Sites / Locations

  • National Taiwan University Hospital Yunlin Branch

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

acupressure group

control group

Arm Description

The participants received modern routing standard therapy accompanied with the round plastic studs of sea-band were placed just on the skin surface of bilateral PC6 acupoints , and then keep the persistent compressive state for 3 minutes per time and three times a day.

The participants received modern routing standard therapy only with general elastic band without bud over PC6 acupoints.

Outcomes

Primary Outcome Measures

Headache duration
duration (if attack less than 4hours which means better response)
Headache severity
Severity by visual analog scale (0~10), if VAS score decreased 2 points which means better results
Headache frequency
how many times headache occurred (if attack < 8 times which means effective)
dosage of pain killers
how many dosage of pain kill taken (if pain killer taken less than 20 pills which means effective therapy)

Secondary Outcome Measures

Calcitonin gene-related peptide (CGRP) level
Check serum CGRP level to evaluate the correlation
Neurokinin A (NKA) level
Check NKA level to realize any discrepancy
the score of 36-Item Short Form Health Survey (SF-36)
Complete form for quality evaluation (score: 0~100, worse to better)

Full Information

First Posted
May 24, 2020
Last Updated
July 11, 2022
Sponsor
National Taiwan University Hospital
Collaborators
China Medical University, Taiwan
search

1. Study Identification

Unique Protocol Identification Number
NCT04429048
Brief Title
Effect of Acupressure in Migraine: Single-blinded, Randomized, Controlled Clinical Trial
Official Title
Effect of Acupressure at PC6 on Headache in Patients With Migraine: Single-blinded, Randomized, Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
July 4, 2020 (Actual)
Primary Completion Date
June 25, 2021 (Actual)
Study Completion Date
July 8, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Taiwan University Hospital
Collaborators
China Medical University, Taiwan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background : Migraine is one of the most complex, prevalent, debilitating neurologic disorder in the world. In clinical experience, there are limitation over western medicine for migraine, especially some extra adverse effects. In traditional Chinese medicine(TCM), there are some reviews and clinical practice point out acupressure at PC6 could relieve nausea/ vomiting and pain while migraine. Recent researches also mention Calcitonin gene-related peptide (CGRP) and Neurokinin A (NKA) in some degree correlated with the mechanism of migraine. Objective: CGRP and NKA play vital roles of migraine. In comparison with oral medication only and PC6 acupressure via oral medication, if there were better effect for migraine control. In addition, investigators evaluate the plasma CGRP and NKA level before and after study to figure out if any positive value and any correlation with acupressure. Method: By single-blinded, randomized, controlled clinical trial, total of 56 patients with migraine were divided equally into acupressure group (modern routing standard therapy plus PC6 acupressure) and control group (modern routing standard therapy). Before intervention, the participants needed to finish the Migraine Disability Assessment (MIDAS) questionnaire evaluation. After 6 weeks, investigators will evaluate the severity, frequencies of headaches and pain-killer consumption as primary outcome. In addition, investigators will investigate if there were change of serum CGRP/NKA level after 6 weeks and the score changes of MOS 36-Item Short-Form Health Survey as secondary outcome. Expected results: The investigators predict that PC6 acupressure may not only reduce severity, frequencies and duration of headaches but also reduce the dose of NSAIDs. In addition, the PC6 acupressure also may reduce levels of serum CGRP and NKA, and improve the quality of life meanwhile.
Detailed Description
Introduction: Migraine is one of the most complex, prevalent, debilitating neurologic disorder and the prevalence higher in female group. In general, there are many kinds of therapy for migraine nowadays including of acute abortion oral drugs such as triptan, ergotamine, non-steroid anti-inflammatory drugs, acetaminophen and preventive agents such as calcium channel blocker (Flunarizine), anti-epileptic drugs (valproic acid, Topiramate, Pregabalin), beta adrenergic-blocker (Propranolol), Selective Serotonin Reuptake Inhibitors(SSRI), anti-emetic agents (Prochlorperazine) and other injection therapy such as Onabotulinum Toxin A or CGRP (Calcitonin gene-related peptide) antagonist etc. The CGRP plays an important role of trigemino-vascular responses in migraine. The serum CGRP levels elevated while migraine attack and chronic migraine, therefore, CGRP is a potential biomarker. In recent studies, higher plasma CGRP level during interictal phase of migraine or chronic migraine is indicated the better response for Onabotulinum Toxin A and reduced plasma CGRP level can relieve the discomfort of migraine. Neurokinin A (NKA) levels of venous blood are significantly higher in responders than these nonresponse before the rizatriptan treatment, whereas reduced the levels of both CGRP and NKA one hours after the treatment . The headache is associated with nausea in about 80% of episodes, vomiting in about 30% in patients with migraine. PC6 is belong to pericardium meridian locates the anterior aspect of forearm between the tendons of the palmaris longus and the flexor carpi radialis, 2 cun proximal to the wrist transverse stripes just on the median nerve . The antiemetic is lower for preventing postoperative nausea and vomiting in the combination PC6 acupoint stimulation than these patients with antiemetic only. Acupuncture at the PC6 is an effective alternative treatment to conventional pharmacological treatment and resulted in almost immediate cessation of intraoperative nausea and vomiting. Therefore, acupressure at PC6 is an effective and safety method for nausea and vomiting. In addition, stimulation at PC6 can activate hypothalamic orexin neurons, and that release orexins to induce analgesia. Taken together, PC6 stimulation can produce effect of both analgesia and antiemetic effects. The present study suppose stimulation at PC6 is beneficial for the treatment of migraine. Therefore, the investigators designed a single-blinded, randomized, controlled trial to evaluate the effect of acupressure at PC6 on headache in patients with migraine. Method and study design: (A) Participants The patients with migraine were enrolled from the outdoor patients (OPD) of neurological department, Yunlin branch of National Taiwan University hospital. The basic laboratory data including peripheral blood cells, Na/K/Ca/Mg, alanine aminotransferase (ALT), creatinine, iron/total iron-binding capacity (TIBC)/ferritin to exclude extremely abnormal metabolic disturbance or liver/renal functional impairment which may cause secondary headache; and the awake electroencephalography (EEG) and brain image including computer tomography (C-T) or magnetic resonance image (MRI) also were done to rule out any intracranial structure lesion prior to the trial. The migraine was diagnosed according to clinical manifestation and criteria from beta version of the third edition of the International Classification of Headache Disorders (ICHD-3). In addition, non-steroid anti-inflammatory drugs (NSAIDs) are used as episodic way while migraine attack and Propranolol (Inderal R) is used as preventive way no matter when migraine attack. In addition, the participants needed to finish the Migraine Disability Assessment (MIDAS) questionnaire evaluation of 6 weeks. (B) Study design: Single-blinded, randomized, controlled clinical trial. (C) Assessment time: before PC6 acupressure (V1), two weeks after acupressure (V2), four weeks after acupressure (V3) and six weeks after acupressure (D) Statistical analysis : Categorical data will be displayed in numbers and percentages, whereas continuous variables will be given as means ± standard deviations or median (Q1, Q3). Differences in categorical variables will be tested using the chi-square test or Fisher exact test and differences in continuous variables will be tested using the two sample independent t test or Mann-Whitney test between groups. The generalized estimating equations (GEE) will be used to compare the change of primary outcomes over time (the four time points (V1-V4)) between two groups. A p value of less than 0.05 will be considered statistically significant. All statistical analyses will be performed using SPSS Statistics 24or R version 3.4.4 . Outcome : The study of the present study predicts that PC6 acupressure may reduce severity of headaches, the frequency of headache attacks and duration of headache, and also reduce the dose of NSAID. In addition, the PC6 acupressure also may reduce levels of serum CGRP and NKA, and also may improve the quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine; Status
Keywords
migraine ,acupressure,CGRP,neurokinin A

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Masking Description
single blind
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
acupressure group
Arm Type
Experimental
Arm Description
The participants received modern routing standard therapy accompanied with the round plastic studs of sea-band were placed just on the skin surface of bilateral PC6 acupoints , and then keep the persistent compressive state for 3 minutes per time and three times a day.
Arm Title
control group
Arm Type
Sham Comparator
Arm Description
The participants received modern routing standard therapy only with general elastic band without bud over PC6 acupoints.
Intervention Type
Device
Intervention Name(s)
Acupressure elastic band (Sea-Band)
Intervention Description
The PC6 acupressure was done via Sea-Band in persistent compressive state for 3 minutes per time and three times a day , then at least 5 days in one week for 6 weeks continuously except modern routine standard therapy
Intervention Type
Device
Intervention Name(s)
General elastic band (no bud)
Intervention Description
general elastic band was put over bilateral PC6 acupoints
Primary Outcome Measure Information:
Title
Headache duration
Description
duration (if attack less than 4hours which means better response)
Time Frame
After 6 weeks , evaluate how many episodes of lesser duration(<4hours) of the two groups
Title
Headache severity
Description
Severity by visual analog scale (0~10), if VAS score decreased 2 points which means better results
Time Frame
After 6 weeks, evaluate the headache severity (VAS score) if any decreased
Title
Headache frequency
Description
how many times headache occurred (if attack < 8 times which means effective)
Time Frame
evaluate total headache episodes after 6 weeks
Title
dosage of pain killers
Description
how many dosage of pain kill taken (if pain killer taken less than 20 pills which means effective therapy)
Time Frame
evaluation total amount of pain-killer consumption after 6 weeks
Secondary Outcome Measure Information:
Title
Calcitonin gene-related peptide (CGRP) level
Description
Check serum CGRP level to evaluate the correlation
Time Frame
1st time: 1 day of sign informed consent ; 2nd time: through study completion, an average of 6 weeks
Title
Neurokinin A (NKA) level
Description
Check NKA level to realize any discrepancy
Time Frame
1st time: 1 day of sign informed consent ; 2nd time: through study completion, an average of 6 weeks
Title
the score of 36-Item Short Form Health Survey (SF-36)
Description
Complete form for quality evaluation (score: 0~100, worse to better)
Time Frame
through study completion, an average of 6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
A. Inclusion criteria Age ranged from 20 to 50-year-old (inclusion) Female or male. Neurological examination was within normal limit. Neither epileptiform discharge from EEG nor abnormality of neuroimage B. Exclusion criteria Headache was results from adverse effects for NSAIDs and Propranolol. Active skin lesion or oozing wound over PC6 acupoints. Pregnancy or lactation. Recent traumatic brain injury or brain tumor. Secondary headache Brain surgical history. Refuse sign informed consent. Extremely abnormal metabolic disturbance (such as iron deficiency anemia, hypo/hypernatremia, hypo/hyperkalemia, hypo/hypercalcemia, hypo/ hypermagnesemia) and liver/renal dysfunction ALT > 3x normal upper limits; creatinine >1.4)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chih-hung Tsai, MD
Organizational Affiliation
National Taiwan University Hospital Yunlin Branch
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Taiwan University Hospital Yunlin Branch
City
Douliu
State/Province
Yunlin County
ZIP/Postal Code
64041
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Effect of Acupressure in Migraine: Single-blinded, Randomized, Controlled Clinical Trial

We'll reach out to this number within 24 hrs